Naltrexone 0.1-0.3% Ophthalmic Solution

• Volume: 6mL or 12mL
• Strength: 0.1%, 0.2%, or 0.3%

References:

1. Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol. 2009;127(11):1468-1473. PMID: 19901203. https://pubmed.ncbi.nlm.nih.gov/19901203/
2. McLaughlin PJ, Sassani JW, Titunick MB, Zagon IS. Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes. BMC Ophthalmol. 2019;19(1):35. PMID: 30760255. https://pubmed.ncbi.nlm.nih.gov/30760255/
3. Liang D, Sassani JW, McLaughlin PJ, Zagon IS. Topical application of naltrexone to the ocular surface of healthy volunteers: tolerability study. J Ocul Pharmacol Ther. 2016;32(2):127-132. PMID: 26720358. https://pubmed.ncbi.nlm.nih.gov/26720358/
4. Arnold TS, Wittenburg LA, Powell CC. Effect of topical naltrexone 0.3% on corneal sensitivity and tear parameters. Vet Ophthalmol. 2014;17(5):328-333. PMID: 24224753. https://pubmed.ncbi.nlm.nih.gov/24224753/

Learn more – Ophthalmic Compounding: Low-Dose Naltrexone (LDN) Eye Drops.